Streetbeat News

VAXX

Vaxxinity Inc

vaxxinity.com

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

vaccines against chronic diseases

Open

0.00

Mkt cap

25K

Volume

1.7K

High

0.00

P/E Ratio

N/A

52-wk high

1.10

Low

0.00

Div yield

N/A

52-wk low

0.00

Vaxxinity, Inc. announced its intention to voluntarily delist and deregister its Class A common stock, causing a sharp decline in its shares by around 55%. Other stocks experienced significant movements, with Matterport, Inc. seeing a jump due to an acquisition announcement by CoStar Group, and various companies reporting gains due to positive developments such as USDA approvals, IPO pricing, and compliance regains. Conversely, several companies faced declines due to negative news such as wind-down activities, delisting determinations, and price reductions.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 5:26 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. NKGen Biotech led the gainers with a 33.8% increase, while Vaxxinity saw the largest decline among the losers, dropping 52.9%. Other notable movers included MSP Recovery, Assure Holdings, ProKidney, iSpecimen, GlucoTrack, Hepion Pharmaceuticals, Bio-Path Holdings, Inhibikase Therapeutics, Telomir Pharmaceuticals, and Ocean Biomedical. Market capitalizations varied widely among these companies, reflecting diverse investor reactions to recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 4:31 pm

U.S. stocks traded higher with the Dow Jones, NASDAQ, and S&P 500 all seeing gains. Albertsons Companies Inc reported upbeat fourth-quarter earnings, while Matterport, Inc announced a significant acquisition deal by CoStar Group, causing its shares to spike. Other notable movements included Moolec Science SA and NewGenIvf Group Limited experiencing substantial share increases, whereas Vaxxinity, Inc, Hepion Pharmaceuticals, Inc, and Warrantee Inc faced sharp declines.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 4:07 pm

U.S. stocks traded higher with the Dow Jones gaining over 100 points. The Chicago Fed National Activity Index rose to +0.15 in March, exceeding expectations. Moolec Science SA, NewGenIvf Group Limited, and SuperCom Ltd. saw significant stock increases, while Vaxxinity, Inc., Hepion Pharmaceuticals, Inc., and Connexa Sports Technologies Inc. experienced notable declines.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 1:41 pm

Vaxxinity's shares are trading lower following the company's announcement of its intention to voluntarily delist and deregister its Class A common stock.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:16 pm

In Monday's pre-market session, health care stocks showed significant movement. Adial Pharmaceuticals (ADIL) and NKGen Biotech (NKGN) led the gainers with over 30% increases in their stock prices, while Vaxxinity (VAXX) and Hepion Pharmaceuticals (HEPA) were among the top losers, with VAXX stock dropping over 60%. The movements were attributed to various factors, including recent earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 12:07 pm

Riot Platforms, Inc. (RIOT) shares rose by 5.3% in pre-market trading, influenced by a 1.5% increase in Bitcoin prices. Other stocks also showed significant movement in pre-market trading, with notable gainers including Complete Solaria, Inc. (CSLR) and The OLB Group, Inc. (OLB), among others. Conversely, Vaxxinity, Inc. (VAXX) and Mingteng International Corporation Inc. (MTEN) were among the pre-market losers.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 9:23 am

In Friday's after-market session, several healthcare stocks showed notable movements. Mobile-health Network (MNDR) led the gainers with a 15.0% increase, while Vaxxinity (VAXX) experienced the largest drop among the losers, declining by 10.7%. Other notable movers included Galera Therapeutics (GRTX) and Titan Pharma (TTNP).

Portfolio Pulse from Benzinga Insights

April 19, 2024 | 8:31 pm

Vaxxinity has announced its plan to voluntarily delist its Class A common stock from the Nasdaq. This decision reflects the company's strategic move, potentially to reduce regulatory burdens and costs associated with being listed on a major exchange.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 8:10 pm

Vaxxinity (NASDAQ:VAXX) reported a Q4 EPS loss of $(0.09), surpassing the analyst consensus estimate of $(0.10) by 10%. This represents a 43.75% improvement over the $(0.16) per share loss from the same quarter last year.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 8:46 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.